Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

References

• Thomas X, Raffoux E, Botton S, . Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group. Leukemia 2007;21:453–461.
   PubMed Web of Science ®Google Scholar
• Feusner JH, Hastings CA. Infections in children with acute myelogenous leukemia. Concepts of management and prevention. J Pediatr Hematol Oncol 1995;17:234–247.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Buzyn A, Leverger G, .; Club de Réflexion sur les Infections en Onco-Hématologie. Epidemiology and risk factors for Gram-positive coccal infections in neutropenia: toward a more targeted antibiotic strategy. Clin Infect Dis 2003;36:149–158.
   Google Scholar
• Tobias JS, Wrigley PF, O’Grady F. Bacterial infection and acute myeloblastic leukaemia: an analysis of two hundred patients undergoing intensive remission induction therapy. Eur J Cancer 1978;14:383–391.
   PubMed Web of Science ®Google Scholar
• Madani TA. Clinical infections and bloodstream isolates associated with fever in patients undergoing chemotherapy for acute myeloid leukemia. Infection 2000;28:367–373.
   PubMed Web of Science ®Google Scholar
• Bennett JM, Catovsky D, Daniel MT, . Proposed revised criteria for the classification of acute myeloid leukemia:a report of the French-American-British Cooperative Group. Ann Intern Med 1985;103:626–629.
   PubMed Web of Science ®Google Scholar
• Castaigne C, Chevret S, Archimbaud E, . Randomized comparison of double induction and timed-sequentialinduction to a “3 + 7” induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood 2004;104:2467–2474.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Davies RB, Schiffer CA, . Intensive post-remission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med 1994;331:896–903.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Cassileth PA, Head DR, . International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642–4649.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, . Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011;52:56–93.
   PubMed Web of Science ®Google Scholar
• Wisplinghoff H, Seifert H, Wenzel RP, . Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 2003;36:1103–1110.
   PubMed Web of Science ®Google Scholar
• Ascioglu S, Rex JH, de Pauw B, . Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002;34:7–14.
   PubMed Web of Science ®Google Scholar
• Thomas X, Raffoux E, Renneville A, . Which AML subsets benefit from leukemic cell priming during chemotherapy? Long-term analysis of the ALFA-9802 GM-CSF study. Cancer 2010;116:1725–1732.
   PubMed Web of Science ®Google Scholar
• World Health Organization. World Health Organization handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva: WHO; 1979. pp 1–45.
   Google Scholar
• Crawford J, Dale DC, Lyman GH. Chemotherapy-induced neutropenia: risks, consequences, and new direction for its management. Cancer 2004;100:228–237.
   PubMed Web of Science ®Google Scholar
• Malagola M, Peli A, Damiani D, . Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 years treated with induction regimens including fludarabine: retrospective analysis of 224 cases. Eur J Haematol 2008;81:354–363.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, . The epidemiology of fungal infections in patients with hematologic malignancies: the SEI-FEM-2004 study. Haematologica 2006;91:1068–1075.
   PubMed Web of Science ®Google Scholar
• Klastersky J, Zinner SH, Calandra T, . Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 1988;24:S35–S45.
   PubMedGoogle Scholar
• Klastersky J, Ameye L, Maertens J, . Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 2007;30 (Suppl. 1):S51–S59.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Rampazzo R, Malena M, . Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients:a meta-analysis. Clin Infect Dis 1996;23:795–805.
   PubMed Web of Science ®Google Scholar
• Rubio M, Palau L, Vivas JR, . Predominance of gram-positive microorganisms as a cause of septicemia in patients with hematological malignancies. Infect Control Hosp Epidemiol 1994;15:101–104.
   PubMed Web of Science ®Google Scholar
• Rabbat A, Chaoui D, Lefebvre A, . Is BAL useful in patients with acute myeloid leukemia admitted in ICU for severe respiratory complications? Leukemia 2008;22:1361–1367.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Gerson SL, Talbot GH, Hurwitz S, . Prolonged granolucytopenia: the major risk factor for invasive aspergillosis in patients with acute leukaemia. Ann Intern Med 1984;100:345–357.
   PubMed Web of Science ®Google Scholar
• Van Gool R. The cost of treating systemic fungal infections. Drugs 2001;61(Suppl. 1):49–56.
   PubMed Web of Science ®Google Scholar
• Martino R, Lopez R, Sureda A, . Risk of reactivation of a recent invasive fungal infection in patients with hematological malignancies undergoing further intensive chemotherapy: a single center experience and review of the literature. Haematologica 1997;82:297–304.
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, Sobel JD, Ruhnke M, . Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005;366:1435–1442.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Denning DW, Patterson TF, . Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002;347:408–415.
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Anaissie EJ, Denning DW, . Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327–360.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Rovira M, Maertens J, . Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010;95:1762–1768.
   PubMed Web of Science ®Google Scholar
• Sonis ST. Oral complications of cancer therapy. In: Devita VT, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. 2nd ed. Philadelphia:JB Lippincott; 1985. pp 2014–2021.
   Google Scholar
• Aksoy DY, Tanriover MD, Uzun O, . Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007;18:183–189.
   PubMed Web of Science ®Google Scholar
• Gorschlüter M, Mey U, Strehl J, . Invasive fungal infections in neutropenic enterocolitis: a systematic analysis of pathogens, incidence, treatment and mortality in adult patients. BMC Infect Dis 2006;6:35.
   PubMed Web of Science ®Google Scholar
• Wolfson JS, Sober AJ. Dermatologic manifestations of infection in the compromised host. In: Rubin RH, Young LS, editors. Clinical approach of infection in the compromised host. 2nd ed. New York:Plenum Medical; 1986. pp 115–130.
   Google Scholar
• Riley LC, Hann IM, Wheatley K, . Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML 10). Br J Haematol 1999;106:436–444.
   PubMed Web of Science ®Google Scholar
• Lehrnbecher T, Varwig D, Kaiser J, . Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93. Leukemia 2004;18:72–77.
   PubMed Web of Science ®Google Scholar
• Robenshtok E, Gafter-Gvili A, Goldberg E, . Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem cell transplantation: systematic review and meta-analysis. J Clin Oncol 2007;25:5471–5489.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston DJ, . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Bucaneve G, Micozzi A, Menichetti F, . Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 2005;353:977–987.
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Nosari A, . Fungal infections in recipients of hematopoietic stem cell transplants: results of the SEIFEM B-2004 study – Sorveglianza Epidemiologica Infezioni Fungine Nelle Emopatie Maligne. Clin Infect Dis 2007;45:1161–1170.
   PubMed Web of Science ®Google Scholar